Business Context and Reporting Period
Zura Bio Limited (ZURA) is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company operates as an emerging growth company and a smaller reporting company. This summary covers the fiscal year ended December 31, 2024.
As of December 31, 2024, Zura had 30 full-time employees and no products approved for commercial sale. The company's pipeline includes three primary assets: tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880).
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(52.4) million | $(60.4) million |
| Net Loss Attributable to Shareholders | $(45.4) million | $(69.2) million |
| Research & Development Expenses | $24.4 million | $44.0 million |
| General & Administrative Expenses | $30.8 million | $18.6 million |
| Cash and Cash Equivalents (Ending) | $176.5 million | $99.8 million |
| Net Cash Used in Operating Activities | $(28.1) million | $(15.1) million |
| Net Cash Provided by Financing Activities | $109.8 million | $121.3 million |
| Accumulated Deficit | $(155.9) million | $(103.5) million |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $8.0 million (13%) compared to 2023. This improvement was driven by a significant decrease in Research and Development (R&D) expenses, partially offset by an increase in General and Administrative (G&A) expenses.
- R&D Expenses: Decreased by $19.6 million (45%). The primary driver was the absence of a $27.2 million in-process research and development (IPR&D) charge related to the 2023 Lilly License acquisition recorded in the prior year. This decrease was partially offset by a $4.5 million milestone payment to Stone Peach and increased personnel and consulting costs.
- G&A Expenses: Increased by $12.1 million (65%). This was primarily due to a $5.9 million non-cash share-based compensation charge related to the modification of awards for the former CEO, increased professional fees (including $1.6 million for the Warrant Exchange), and higher executive compensation.
- Liquidity: Cash and cash equivalents increased by $76.7 million, driven by $112.5 million in gross proceeds from the April 2024 Private Placement and $5.5 million from At-The-Market (ATM) sales, despite operating cash outflows.
- Warrant Exchange: In August 2024, the company completed an exchange offer, converting all outstanding public and private placement warrants into Class A Ordinary Shares, eliminating the warrant liability.
Guidance, Outlook, and Risks
Clinical Development Outlook
- Tibulizumab (ZB-106): The company initiated the TibuSURE Phase 2 study in systemic sclerosis (SSc) in December 2024. Topline data is expected in Q4 2026. A Phase 2 study in hidradenitis suppurativa (HS) is expected to initiate in Q2 2025.
- Crebankitug (ZB-168) & Torudokimab (ZB-880): The company is actively assessing the competitive landscape and evaluating potential therapeutic indications for these assets. No specific Phase 2 initiation dates were provided for these assets in the filing.
Liquidity and Capital Resources
Management believes existing cash, cash equivalents, and short-term marketable securities ($176.5 million as of Dec 31, 2024) are sufficient to fund operations through 2027. The company has an ATM facility with $114.0 million remaining available for sale.
Key Risks and Contingencies
- Going Concern: The company has incurred significant losses since inception and expects to continue doing so. It has no revenue and relies on financing to fund operations.
- License Dependencies: The business relies heavily on licenses from Eli Lilly (for tibulizumab and torudokimab) and Pfizer (for crebankitug). Failure to meet obligations could result in termination of these rights.
- Manufacturing Risks: The company relies on third-party manufacturers. Torudokimab manufacturing was moved from WuXi Biologics (China) to the UK due to geopolitical scrutiny, but supply chain risks remain.
- Regulatory Approval: No products are approved. Clinical trials may fail to demonstrate efficacy or safety, preventing regulatory approval.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "through 2027" liquidity estimate given the high burn rate and potential for accelerated clinical spending.
- License Obligations: Review the specific milestone triggers and royalty rates in the Lilly and Pfizer agreements to understand future cash outflow requirements.
- Share-Based Compensation: Assess the impact of the $5.9 million CEO award modification on future G&A expenses and potential dilution.
- Manufacturing Supply Chain: Confirm the status of the torudokimab manufacturing transfer and the availability of drug substance for future trials.
- ATM Utilization: Monitor the remaining $114.0 million ATM facility and the pricing of recent sales ($1.75/share in Q1 2025) for signs of dilution pressure.